In vitro characterization of a nineteenth-century therapy for smallpox

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Arndt, William ^a   Mitnik, Chandra ^a   Denzler, Karen L ^a   White, Stacy ^a   Waters, Robert ^a,b   Jacobs, Bertram L ^a   Rochon, Yvan ^b,c   Olson, Victoria A ^d   Damon, Inger K ^d   Langland, Jeffrey O ^a,b  

^a ARIZONA STATE UNIVERSITY   (United States)

^b Southwest College Naturopathic Med   (United States)

^c Herbal Vitality Inc   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ASTRAGALUS MEMBRANACEUS EXTRACT; CIDOFOVIR; ECHINACEA ANGUSTIFOLIA EXTRACT; GLYCYRRHIZA EXTRACT; MESSENGER RNA; PLANT EXTRACT; SARRACENIA PURPUREA EXTRACT; TRAMETES VERSICOLOR EXTRACT; UNCLASSIFIED DRUG; CYTOSINE; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; ASTRAGALUS MEMBRANACEUS; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG EFFICACY; DRUG MECHANISM; ECHINACEA; ECHINACEA ANGUSTIFOLIA; GLYCYRRHIZA; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MONKEYPOX VIRUS; NONHUMAN; PLANT ROOT; PROTEIN SYNTHESIS INHIBITION; RABBIT; SARRACENIA PURPUREA; SARRACENIACEAE; SMALLPOX; SMALLPOX VIRUS; TRAMETES VERSICOLOR; VACCINIA VIRUS; VIRUS INHIBITION; VIRUS PLAQUE; VIRUS TRANSCRIPTION; ANIMAL; CANADA; CELL LINE; CHEMISTRY; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; HISTORY; METHODOLOGY; PHYTOTHERAPY; REAL TIME POLYMERASE CHAIN REACTION; UNITED STATES; VIRUS REPLICATION;

MONKEYPOX VIRUS; ORTHOPOXVIRUS; POXVIRIDAE; SARRACENIA PURPUREA; VACCINIA VIRUS; VARIOLA VIRUS;

ANIMALS; CANADA; CELL LINE; CYTOSINE; FLUORESCENT ANTIBODY TECHNIQUE; HELA CELLS; HISTORY, 19TH CENTURY; HUMANS; PHOSPHONIC ACIDS; PHYTOTHERAPY; PLANT EXTRACTS; RABBITS; REAL-TIME POLYMERASE CHAIN REACTION; SARRACENIACEAE; SMALLPOX; UNITED STATES; VARIOLA VIRUS; VIRUS REPLICATION;

EID: 84857976144     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032610     Document Type: Article

References (33)

1. Miles HS, (1862) On the employment of the Sarracenia purpurea, or Indian Pitcher Plant, as a remedy for smallpox. The Lancet 80: 430-431.
2. Miles HC, (1862) On some cases of small-pox treated by the Sarracenia purpurea. The Lancet 80: 615-616.
3. Millspaugh CF, (1887) American Medicinal Plants: An Illustrated and Descriptive Guide to the American Plants Used as Homeopathic Remedies: Their History, Preparation, Chemistry and Physiological Effect, (New York and Philadelphia).
4. Clarke JH, (1900) A Dictionary of Practical Materia Medica (The Homeopathic Publishing Company, London).
5. Kress H Henriette's Herbal Homepage website. Available: http://www.henriettesherbal.com/eclectic/spec-med/sarracenia.html. Accessed 2009 Sept 3.
6. Scudder JM, (1870) Specific Medication and Specific Medicines, (Scudder Bros. Co., Cincinnati).
7. Felter HW, Lloyd JU, (1898) King's American Disensatory.
8. Grant WH, (1864) Two cases of small-pox successfully treated by Sarracenia purpurea. The Lancet 83: 161.
9. Renshaw CJ, (1863) Treatment of small-pox by Sarracenia purpurea. British Medical Journal 1: 127.
10. Vandaveer C, (2001) Could a carnivorous plant be a cure for smallpox? website Available: http://www.killerplants.com/herbal-folklore/20010730.asp. Accessed 2010 Feb 4.
11. Marson JF, (1863) Report of the trial of Sarracenia purpurea, or Pitcher Plant, in smallpox. The Lancet 82: 6-7.
12. Taylor J, (1863) On the efficacy of Sarracenia purpurea in arresting the progress of small-pox. The Lancet 82: 664-665.
13. Lloyd FE, (1942) The Carnivorous Plants (Chronica Botanica Company, Waltham, Mass., U.S.A.).
14. Ellison AM, Buckley HL, Miller TE, Gotelli NJ, (2004) Morphological variation in Sarracenia purpurea (Sarraceniaceae): geographic, environmental, and taxonomic correlates. American J of Botany 91: 1930-1935.
15. Kern ER, Hartline C, Harden E, Keith K, Rodriguez N, et al. (2002) Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob Agents Chemother 46: 991-995.
16. Ciustea M, Silverman JE, Druck Shudofsky AM, Ricciardi RP, (2008) Identification of non-nucleoside DNA synthesis inhibitors of vaccinia virus by high-throughput screening. J Med Chem 51: 6563-6570.
17. Neyts J, De Clercq E, (1993) Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. J Med Virol 41: 242-246.
18. Smee DF, Bailey KW, Sidwell RW, (2001) Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir. Antivir Chem Chemother 12: 71-76.
19. Chen N, Li G, Liszewski MK, Atkinson JP, Jahrling PB, et al. (2005) Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology 340: 46-63.
20. Lalezari JP, Stagg RJ, Kuppermann BD, Holland GN, Kramer F, et al. (1997) Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann Intern Med 126: 257-263.
21. Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, et al. (2005) An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J Virol 79: 13139-13149.
22. Institute of Medicine (U.S.). (1999) Committee on the Assessment of Future Scientific Needs for Live Variola Virus. Assessment of future scientific needs for live variola virus, (National Academy Press, Washington, D.C.).
23. Brandt TA, Jacobs BL, (2001) Both carboxy- and amino-terminal domains of the vaccinia virus interferon resistance gene, E3L, are required for pathogenesis in a mouse model. J Virol 75: 850-856.
24. Chang HW, Jacobs BL, (1993) Identification of a conserved motif that is necessary for binding of the vaccinia virus E3L gene products to double-stranded RNA. Virology 194: 537-547.
25. Langland JO, Jacobs BL, (2004) Inhibition of PKR by vaccinia virus: role of the N- and C-terminal domains of E3L. Virology 324: 419-429.
26. Cooper JA, Moss B, (1978) Transcription of vaccinia virus mRNA coupled to translation in vitro. Virology 88: 149-165.
27. Wollenberg A, Engler R, (2004) Smallpox, vaccination and adverse reactions to smallpox vaccination. Curr Opin Allergy Clin Immunol 4: 271-275.
28. Martin KW, Ernst E, (2003) Antiviral agents from plants and herbs: a systemic review. Antivir Ther 8: 77-90.
29. Miles DH, Kokpol U, Zalkow LH, Steindel SJ, Nabors JB, (1974) Tumor inhibitors. I. Preliminary investigation of antitumor activity of Sarracenia flava. J Pharm Sci 63: 613-615.
30. Parker S, Handley L, Buller RM, (2008) Therapeutic and prophylactic drugs to treat orthopoxvirus infections. Future Virology 3: 595-612.
31. Kern ER, Harden E, Keith K, Rodriguez N, Beadle JR, Hostetler KY, (2002) Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob Agents Chemother 46: 991-995.
32. Bolken TC, (2010) Tecovirimat for smallpox infections. Drugs Today (Barc) 46: 109-117.
33. Jesus DM, Moussatche N, Damaso CR, (2009) In vitro activity of cidofovir against the emerging Cantagalo virus and the smallpox vaccine strain IOC. Int J of Antimicrobial Agents 33: 75-79.